30 years of historical data (1996–2025) · Healthcare · Medical - Healthcare Plans
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CVS Health Corporation trades at 70.7x earnings, 177% above its 5-year average of 25.5x, sitting at the 97th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 220%. On a free-cash-flow basis, the stock trades at 16.1x P/FCF, 62% above the 5-year average of 9.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $125.4B | $100.9B | $56.7B | $101.9B | $123.3B | $137.1B | $89.7B | $96.9B | $68.4B | $74.2B | $85.1B |
| Enterprise Value | $210.5B | $185.9B | $131.0B | $173.0B | $181.1B | $203.7B | $166.9B | $180.3B | $137.8B | $99.5B | $109.3B |
| P/E Ratio → | 70.73 | 57.09 | 12.27 | 12.20 | 28.59 | 17.34 | 12.51 | 14.62 | — | 11.26 | 16.10 |
| P/S Ratio | 0.31 | 0.25 | 0.15 | 0.28 | 0.38 | 0.47 | 0.33 | 0.38 | 0.35 | 0.40 | 0.48 |
| P/B Ratio | 1.66 | 1.34 | 0.75 | 1.33 | 1.72 | 1.82 | 1.29 | 1.51 | 1.17 | 1.97 | 2.31 |
| P/FCF | 16.07 | 12.92 | 8.96 | 9.80 | 9.17 | 8.71 | 6.68 | 9.33 | 10.02 | 12.19 | 10.75 |
| P/OCF | 11.79 | 9.48 | 6.22 | 7.59 | 7.62 | 7.51 | 5.66 | 7.55 | 7.72 | 9.27 | 8.40 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
CVS Health Corporation's enterprise value stands at 14.0x EBITDA, 21% above its 5-year average of 11.7x. This is roughly in line with the Healthcare sector median of 14.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.46 | 0.35 | 0.48 | 0.56 | 0.70 | 0.62 | 0.70 | 0.71 | 0.54 | 0.62 |
| EV / EBITDA | 14.04 | 12.40 | 9.99 | 9.56 | 14.87 | 11.45 | 9.10 | 11.02 | 20.44 | 8.28 | 8.50 |
| EV / EBIT | 20.27 | 35.38 | 14.38 | 12.51 | 22.29 | 15.62 | 13.17 | 14.98 | 34.23 | 10.67 | 11.25 |
| EV / FCF | — | 23.82 | 20.71 | 16.65 | 13.46 | 12.94 | 12.43 | 17.35 | 20.18 | 16.35 | 13.81 |
Margins and return-on-capital ratios measuring operating efficiency
CVS Health Corporation earns an operating margin of 2.6%. Operating margins have compressed from 3.8% to 2.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 2.3% is modest. ROIC of 5.0% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 13.8% | 13.8% | 13.8% | 15.2% | 16.9% | 17.8% | 18.3% | 17.7% | 16.2% | 15.4% | 16.2% |
| Operating Margin | 2.6% | 2.6% | 2.3% | 3.8% | 2.5% | 4.6% | 5.2% | 4.7% | 2.1% | 5.2% | 5.8% |
| Net Profit Margin | 0.4% | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | 2.7% | 2.6% | -0.3% | 3.6% | 3.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.3% | 2.3% | 6.1% | 11.2% | 5.9% | 11.0% | 10.7% | 10.8% | -1.2% | 17.8% | 14.4% |
| ROA | 0.7% | 0.7% | 1.8% | 3.5% | 1.9% | 3.5% | 3.2% | 3.2% | -0.4% | 7.0% | 5.7% |
| ROIC | 5.0% | 5.0% | 4.3% | 7.4% | 4.4% | 6.9% | 7.1% | 6.5% | 3.2% | 11.5% | 12.6% |
| ROCE | 6.1% | 6.1% | 5.0% | 8.3% | 4.9% | 8.0% | 8.2% | 7.5% | 3.7% | 14.4% | 15.1% |
Solvency and debt-coverage ratios — lower is generally safer
CVS Health Corporation carries a Debt/EBITDA ratio of 6.2x, which is highly leveraged (94% above the sector average of 3.2x). Net debt stands at $85.1B ($93.6B total debt minus $8.5B cash). Interest coverage of just 1.7x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.24 | 1.24 | 1.09 | 1.04 | 0.99 | 1.01 | 1.22 | 1.39 | 1.25 | 0.72 | 0.75 |
| Debt / EBITDA | 6.24 | 6.24 | 6.32 | 4.38 | 5.81 | 4.27 | 4.63 | 5.44 | 10.90 | 2.25 | 2.14 |
| Net Debt / Equity | — | 1.13 | 0.98 | 0.93 | 0.81 | 0.88 | 1.11 | 1.30 | 1.18 | 0.67 | 0.66 |
| Net Debt / EBITDA | 5.68 | 5.68 | 5.67 | 3.93 | 4.75 | 3.74 | 4.21 | 5.09 | 10.29 | 2.11 | 1.88 |
| Debt / FCF | — | 10.90 | 11.75 | 6.85 | 4.30 | 4.23 | 5.75 | 8.02 | 10.16 | 4.16 | 3.05 |
| Interest Coverage | 1.68 | 1.68 | 3.08 | 5.20 | 3.55 | 5.21 | 4.36 | 3.96 | 1.54 | 8.79 | 9.00 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.84x is below 1.0, meaning current liabilities exceed current assets — though the company's $8.5B cash position helps mitigate short-term liquidity concerns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.84 | 0.84 | 0.81 | 0.86 | 0.95 | 0.88 | 0.91 | 0.94 | 1.03 | 1.02 | 1.18 |
| Quick Ratio | 0.63 | 0.63 | 0.60 | 0.63 | 0.67 | 0.62 | 0.61 | 0.62 | 0.65 | 0.52 | 0.62 |
| Cash Ratio | 0.12 | 0.12 | 0.13 | 0.14 | 0.23 | 0.18 | 0.18 | 0.15 | 0.15 | 0.06 | 0.13 |
| Asset Turnover | — | 1.54 | 1.47 | 1.43 | 1.41 | 1.25 | 1.16 | 1.15 | 0.99 | 1.94 | 1.88 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CVS Health Corporation returns 2.7% to shareholders annually primarily through dividends. The payout ratio exceeds 100% at 192.1%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 1.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.7% | 3.4% | 6.0% | 3.1% | 2.4% | 1.9% | 2.9% | 2.7% | 3.0% | 2.8% | 2.2% |
| Payout Ratio | 192.1% | 192.1% | 73.1% | 37.5% | 67.4% | 32.8% | 36.6% | 39.2% | — | 30.9% | 34.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.4% | 1.8% | 8.2% | 8.2% | 3.5% | 5.8% | 8.0% | 6.8% | — | 8.9% | 6.2% |
| FCF Yield | 6.2% | 7.7% | 11.2% | 10.2% | 10.9% | 11.5% | 15.0% | 10.7% | 10.0% | 8.2% | 9.3% |
| Buyback Yield | 0.0% | 0.0% | 5.3% | 2.0% | 2.8% | 0.0% | 0.0% | 0.0% | 0.0% | 5.9% | 5.2% |
| Total Shareholder Yield | 2.7% | 3.4% | 11.3% | 5.1% | 5.2% | 1.9% | 2.9% | 2.7% | 3.0% | 8.6% | 7.4% |
| Shares Outstanding | — | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.0B | $1.0B | $1.1B |
Compare CVS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 | |
| $364B | 30.3 | 17.9 | 22.6 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 | |
| $74B | 12.6 | 8.3 | 8.8 | 9.5% | 3.3% | 14.3% | 10.4% | 2.7 | |
| $84B | 15.5 | 11.2 | 26.6 | 25.6% | 4.1% | 13.3% | 9.1% | 3.4 | |
| $43B | 36.7 | 22.9 | 115.5 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 | |
| $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 | |
| $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 | |
| $1.0T | 47.8 | 34.3 | 115.6 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 | |
| $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 | |
| $550B | 39.4 | 19.1 | 27.7 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 | |
| $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Deep dive into CVS consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CVS stock.
CVS Health Corporation's current P/E ratio is 70.7x. The historical average is 27.0x. This places it at the 97th percentile of its historical range.
CVS Health Corporation's current EV/EBITDA is 14.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.7x.
CVS Health Corporation's return on equity (ROE) is 2.3%. The historical average is 11.3%.
Based on historical data, CVS Health Corporation is trading at a P/E of 70.7x. This is at the 97th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CVS Health Corporation's current dividend yield is 2.72% with a payout ratio of 192.1%.
CVS Health Corporation has 13.8% gross margin and 2.6% operating margin.
CVS Health Corporation's Debt/EBITDA ratio is 6.2x, indicating high leverage. A ratio above 4x may signal elevated financial risk.